Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2022 | Challenges with bringing novel immune therapies to MDS

Eric Padron • 9 Dec 2022
ASH 2022
Myelodysplastic Syndromes Checkpoint inhibitors

Eric Padron, MD, Moffitt Cancer Center, Tampa, FL, highlights challenges with bringing novel immune therapies to myelodysplastic syndromes (MDS). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eric Padron

Unanswered questions in CMML: timing of treatment initiation to delay progression
0:59
Unanswered questions in CMML: timing of treatment initiation to delay progression
Eric Padron • 22 Aug 2025
The unique challenges that underlie the lack of therapeutic advances in CMML to date
1:36
The unique challenges that underlie the lack of therapeutic advances in CMML to date
Eric Padron • 22 Aug 2025
Using molecular profiling and genomic insights to improve the management of CMML
1:18
Using molecular profiling and genomic insights to improve the management of CMML
Eric Padron • 22 Aug 2025
Updates in the field of CMML: changes in diagnostic criteria & the growing number of clinical trials
1:31
Updates in the field of CMML: changes in diagnostic criteria & the growing number of clinical trials
Eric Padron • 22 Aug 2025

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Eric Padron • 6 Dec 2025
Practice-changing highlights in MDS from ASH 2025: the VERONA trial and triplet combinations
1:07
Practice-changing highlights in MDS from ASH 2025: the VERONA trial and triplet combinations
Eric Padron • 6 Dec 2025
Outcomes of HMA plus venetoclax in HR-MDS: an analysis from the icMDS validate database
5:58
Outcomes of HMA plus venetoclax in HR-MDS: an analysis from the icMDS validate database
Eric Padron • 16 Dec 2025
Olutasidenib with co-targeted therapy in R/R IDH1-mutated myeloid malignancies: Phase II trial
1:30
Olutasidenib with co-targeted therapy in R/R IDH1-mutated myeloid malignancies: Phase II trial
Eric Padron • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals